THE DEAL, AT A GLANCE
From the announcementHuasaibio
Cell therapy development What it does] HUASAIBIO, established in March 2019, is a biopharmaceutical company dedicated to the development of novel innovative cell therapies.From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗Who is involvedBacked by Salvage TherapyFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗What happenedHuasaibio raised $30M Series B, announced 2026-11-09From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗Why it mattersHuasaibio's $30M Series B adds to funding activity classified as Unclassified in the Capvizr database.From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗
Huasaibio · Financing Record
Explore source-linked visual explanations for Huasaibio. Unsupported claims are withheld while source review continues.
Record 15676 · Recorded date: 2026-11-09
Explore company records →